Navigation Links
Insulet Reports Third Quarter 2008 Results
Date:11/6/2008

volume output of approximately 200,000 OmniPods per month in the third quarter.

-- As part of Insulet's efforts to further demonstrate the clinical and functional benefits of the OmniPod System and expand the market for its potential uses, the Company is supporting the first investigator initiated clinical trial of the OmniPod System to deliver concentrated U500 insulin to patients with Type 2 diabetes. The study, which completed enrollment in the third quarter, is being conducted by Dr. Wendy Lane at the Mountain Diabetes and Endocrine Center in Asheville, NC. The first subjects will complete the one-year trial in the fourth quarter of 2008 and the full study is expected to be completed in 2009.

Conference Call

Insulet will host a conference call on Thursday, November 6, 2008 at 5:00PM Eastern time to discuss the Company's third quarter 2008 results and present information concerning its business, strategies and outlook. To listen to the conference call, please dial 800-329-9097 for domestic callers and 617-614-4929 for international callers. The passcode is 94585068. A replay of the conference call will be available two hours after the start of the call through November 19, 2008 by dialing 888-286-8010 (domestic) and 617-801-6888 (international), passcode 97337909. An online archive of the conference call will also be available by accessing the Investor Information section of the company's website at http://investors.insulet.com.

Non-GAAP financial information

The Company reports both GAAP revenue and non-GAAP revenue. Non-GAAP revenue is equal to GAAP revenue excluding the impact of a change to the Company's estimate of deferred revenue. Prior to January 1, 2008, the Company deferred the revenue and related costs of revenue for all initial customer shipments until a 45-day right of return had lapsed. With the accumulation of approximately 2 years of data for sales and retu
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
2. Insulet Corporation Announces Pricing of Secondary Public Offering
3. Insulet Corporation to Report Third Quarter 2007 Financial Results on Wednesday, November 14th
4. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
5. Insulet Corporation and DexCom Announce Development Agreement
6. Insulet Corporation to Present at the Seventh Annual JMP Securities Research Conference on May 20, 2008
7. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
8. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
9. Insulet Corporation Announces Private Offering of $65 Million of Convertible Senior Notes
10. Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes
11. Insulet Corporation to Present at the William Blair & Company 28th Annual Growth Stock Conference on June 19, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... 23, 2014 Locks-Magnetic.com, a notable magnetic ... Moreover, all the new products are available at low ... manager is proud of the new emergency doors. The ... And customers can choose from several colors. All of ... quality emergency door release is not as easy as ...
(Date:11/23/2014)... November 23, 2014 SWAccessControl.com's high quality ... market. Recently, the company has announced its new collection ... offer on these high quality power suppliers. All the ... off. The special offer lasts until Dec. 20, 2014. ... of them have been supporting it for a long ...
(Date:11/23/2014)... Asher Milgrom, is a celebrity doctor ... was recently featured on International Business Times. ... of American Medical Aesthetics & Wellness, also known as ... scholarship to attend an M.D./Ph.D program at University of ... of Chicago, where his field of study was neuro-biochemistry. ...
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/23/2014)... City, Utah (PRWEB) November 23, 2014 ... health insurance reimbursement for small businesses, announced their ... book, The End of Employer-Provided Health Insurance. ... insurance is the greatest financial risk facing most ... facing U.S. employers, small and large, when it ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2
... active may help to tackle health threats, study says ... large body size, former professional football players aren,t at ... that looked at 201 retired NFL players. , The ... group of men from the population-based Dallas Heart Study ...
... -- The angiotensin system inhibitor irbesartan did not improve outcomes ... left ventricular ejection fraction. -- ... predominantly affects women and older patients; ... therapies is critical. NEW ORLEANS, Nov. 11 An angiotensin ...
... prevention trial on low-dose aspirin in diabetics,Japanese investigators report ... preventing the primary endpoints of all atherosclerotic events,although it ... - Low-dose aspirin was also associated with a reduced ... a subgroup of diabetics who,were over age 65., ...
... highlights:, -- Individually tailored doses of ... month as measured by platelet reactivity,monitoring by ... measures a,patient,s anti-platelet response to clopidogrel., ... bleeding events,between treatment and control groups., ...
... Study highlights:, - In a randomized, double-blind study ... C-reactive protein (hsCRP) greater than or equal to,2, those ... 31 heart attacks,and 33 strokes compared to 68 and ... analysis showed similar findings across gender, race,ethnicity and Framingham ...
... N.J., Nov. 11, 2008) The F.M. Kirby Foundation of ... Nursing at Rutgers, The State University of New Jersey, to ... Jersey residents. , The grant will also fund the work ... and service in the best academic tradition, said Interim Dean ...
Cached Medicine News:Health News:Retired NFL Players Don't Face Greater Heart Risk 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 2Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 4Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 2Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 2Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 4Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 5
(Date:11/21/2014)... , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... the Piper Jaffray 26 th Annual Healthcare Conference in ... the Piper Jaffray conference is scheduled for 8:00 am EST (5:00 ... webcast, and the webcast can be accessed via the Investor Relations ... of the webcast will be archived for 30 days on the ...
(Date:11/21/2014)... Nov. 20, 2014 Oxis International, Inc. (OXIS) (OXI.PA) ... election of Anthony J. Cataldo as Chief Executive ... Effective November 19, 2014, Ken Eaton resigned his ... of Directors of Oxis International, Inc. to pursue new opportunities. ... named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... CPHD ) today announced that Robert Kwiatkowski, ... of Infectious Disease Research and Development, reporting to David ... impressive menu of eleven highly regarded Xpert® tests for ... extend our leadership with next-generation products, including a number ...
... BETHLEHEM, Pa., June 22, 2011 In a ... of diazepam (NRL-1) achieved positive clinical results in ... was designed and manufactured at Particle Sciences.  In ... pharmacokinetic profile comparable to that reported in the ...
Cached Medicine Technology:Cepheid Appoints Vice President of Infectious Disease Research & Development 2Cepheid Appoints Vice President of Infectious Disease Research & Development 3Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam) 2
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Medicine Products: